The answers will be critical to the development of drugs attempting to modulate the force- and motion-generating capacity of myosins to treat a myriad of diseases, including various forms of muscle weakness and heart failure, because it is essential to identify which step of the cross-bridge cycle to target to purposefully enhance or inhibit the force- and motion-generating capacity of myosin (Auguin et al., 2024; Lam et al., 2023; Scott et al., 2024; Woody et al., 2018). The gene discussed is MYH14; the disease is heart failure.